Dzekova-Vidimliski Pavlina, Sikole Aleksandar
University Hospital of Nephrology, Skopje - Republic of Macedonia.
Int J Artif Organs. 2017 Feb 10;39(12):590-595. doi: 10.5301/ijao.5000548. Epub 2017 Feb 1.
Hepatitis C virus (HCV) infection is highly prevalent among patients treated with maintenance hemodialysis and is an important cause of morbidity and mortality. It is necessary to determine the HCV genotype and the viral load to monitor the clinical and laboratory features and to establish an optimal antiviral treatment strategy. Antiviral treatments are presented with a standard interferon-based regimen and new direct-acting antiviral agents. The advent of direct-acting antivirals has improved the efficacy and safety of HCV treatment for most patients, even in difficult-to-treat populations such as patients on hemodialysis. HCV treatment with direct-acting antivirals in hemodialysis patients is highly effective, with viral eradication rates similar to those seen in patients without chronic kidney disease and with acceptable adverse event profiles.
丙型肝炎病毒(HCV)感染在接受维持性血液透析的患者中非常普遍,是发病和死亡的重要原因。确定HCV基因型和病毒载量对于监测临床和实验室特征以及制定最佳抗病毒治疗策略很有必要。抗病毒治疗包括基于标准干扰素的方案和新型直接抗病毒药物。直接抗病毒药物的出现提高了大多数患者HCV治疗的疗效和安全性,即使在诸如血液透析患者等难以治疗的人群中也是如此。血液透析患者使用直接抗病毒药物进行HCV治疗非常有效,病毒根除率与无慢性肾脏病患者相似,且不良事件情况可接受。